Is arcalyst a biologic?

Is Arcalyst (rilonacept) considered a biologic?

Yes. Arcalyst (rilonacept) is a biologic medicine. It is a recombinant fusion protein designed to act as a “cytokine trap” that binds inflammatory signaling molecules in the body.

Why does Arcalyst fall under the “biologic” category?

Biologics are typically made using living systems (or are derived from biological materials) and are larger, more complex molecules than standard small-molecule drugs. Arcalyst’s mechanism and structure fit that biologic approach: it is a engineered protein therapy intended to bind specific cytokines.

Is Arcalyst a monoclonal antibody?

No. Arcalyst is not a monoclonal antibody. It is a fusion protein cytokine trap, which is a different biologic class than monoclonal antibodies.

What does this mean for biosimilars?

Because Arcalyst is a biologic (and specifically a fusion protein), biosimilar pathways and naming follow the biologics/biosimilars framework rather than the generic small-molecule pathway.